Richard Scheller
Richard H. Scheller is an American neuroscientist who studied how nerve cells release neurotransmitters at StanfordStanford UniversityStanford University is a research university in California founded by Leland and Jane Stanford in 1885 and opened in 1891.Open the full entry. He went on to lead research and early development at Genentech and therapeutics research at 23andMe23andMe23andMe is a consumer genetics and research brand offering ancestry and health-risk services. It is now operated by 23andMe Research Institute, a nonprofit based in Palo Alto, California.Open the full entry. He shared the 2010 Kavli Prize in Neuroscience and the 2013 Albert Lasker Basic Medical Research Award.
Contents9 sections
Key facts
From 1953Family and a basement laboratory outside Milwaukee
Scheller was born in Milwaukee, WisconsinWisconsinWisconsin is a state in the north-central United States; its capital is Madison and its largest city is Milwaukee. Wisconsin was admitted to the Union on May 29, 1848, as the 30th state, and the 2020 census (April 1, 2020) counted 5,893,718 residents.Open the full entry, on October 30, 1953, and grew up in its suburbs. His father was a social worker who became a hospital administrator. His mother looked after the household, went to college after he did and became an artist. He displayed her work in his own home. As a child he kept the periodic table on his bedroom wall, had a microscope and chemistry sets in the basement, and brought home pond water and insects to examine.[1][2]
1975–1982Training in Wisconsin, California and New York
As a freshman he read Molecular Biology of the Gene in a week. His chemistry professor Bassam Shakhashiri became an early mentor. Scheller earned a biochemistry degree at Wisconsin–Madison in 1975 and a chemistry PhD at Caltech in 1980. He held postdoctoral appointments at Caltech and Columbia. Working with Richard Axel and Eric Kandel at Columbia brought him from molecular biology into neuroscience.[1][3]
1982–2001Synapse research and family at Stanford
He joined Stanford as an assistant professor in 1982, spent nineteen years in departments including biological sciences and molecular and cellular physiology, and became a Howard Hughes Medical Institute investigator. He studied how neurons release chemical signals at synapses. Neuroscientist Susan McConnell opened a laboratory next to his and they eventually married. In his Kavli autobiography he recalled that she accepted his eleventh proposal. When he wrote the account, they lived on the Stanford campus with two dogs and a collection of African art.[1][2][4]
2001–2014Genentech research leadership and science prizes
After discussions with Genentech CEO Art Levinson, he joined the company in 2001 as senior vice president for research. He subsequently led research and early development, served on the executive committees of both Genentech and Roche and finished his tenure in 2014. From 2004 he also held an adjunct professorship in Biochemistry and Biophysics at UCSF. His work on neurotransmitter release earned the 1997 US National Academy of Sciences molecular biology award, the 2010 Kavli Prize in Neuroscience and the 2013 Lasker basic medical research award. He shared the Kavli Prize with James Rothman and Thomas Südhof.[1][2][4][5][6]
From 201523andMe, BridgeBio and service on public institutions’ boards
From 2015 to 2019 he was 23andMe’s head of therapeutics and chief scientific officer. He joined the BridgeBio Pharma board in 2018 and became chair of research and development in 2019. He was elected a Caltech trustee and also served as a trustee of the Fine Arts Museums of San Francisco.[4][3]
Scheller served on BridgeBio’s board from 2018 to 2023 in addition to his R&D chairmanship. He was a director of Xenon Pharmaceuticals from 2015 to 2020 and ORIC from 2015 to 2021, and chaired DICE Therapeutics from 2015 to 2023. He joined the 23andMe board in 2019 and resigned alongside six other non-employee directors on September 17, 2024. Maze’s 2026 proxy gives January 2018 to February 2021 for his BridgeBio board service. BridgeBio’s own filing records the resignation taking effect on February 21, 2023.[6][7][8][9]
November 2023Recalling the creation of a therapeutics division
At 20:39 in Sequoia’s episode he explained that his executive position required Genentech to announce his retirement publicly. At 21:31 he recalled that his first strategic plan at 23andMe included the people the company would need to hire. At 23:12 he described being shown a desk on his first day. At 27:23 he discussed the conviction and commitment needed to turn an idea into a research division.[10][11]
2026Biotechnology company boards and institutional trusteeships
In its 2026 proxy Alector identified Scheller as a director and listed his directorships at Maze Therapeutics, Aarvik Therapeutics, Trace Neuroscience, Xaira Therapeutics and GondolaBio. He was also a Caltech trustee and served on the board of the Corporation of the Fine Arts Museums of San Francisco. Aarvik listed him as an independent director and chair of its scientific advisory board. He joined Alector’s board and scientific advisory board in October 2018 and became co-chair of its Strategic Portfolio Advice and Review Committee in December 2019. Maze dated his appointment to its board to June 2019.[12][6][13][8]
Related Organizations, Websites and Public Accounts
Stanford University: Former professor. Official website: https://www.stanford.edu/ (opens in a new window). Genentech: Former head of research and early development. Official website: https://www.gene.com/ (opens in a new window). University of California, San Francisco: Adjunct professor. Official website: https://www.ucsf.edu/ (opens in a new window).[4][5]
23andMe: Former head of therapeutics and chief scientific officer. Official website: https://www.23andme.com/ (opens in a new window). BridgeBio Pharma: Chair of research and development from 2019. Official website: https://bridgebio.com/ (opens in a new window).[4]
California Institute of Technology: Trustee. Official website: https://www.caltech.edu/ (opens in a new window)[12][14]
Xenon Pharmaceuticals: Board service. Official website: https://www.xenon-pharma.com/ (opens in a new window)[6][15]
ORIC Pharmaceuticals: Board service. Official website: https://oricpharma.com/ (opens in a new window)[6][16]
DICE Therapeutics: Former board chair. Record of service: https://www.sec.gov/Archives/edgar/data/1653087/000119312526186928/alec-20260421.htm (opens in a new window)[6]
Alector: Board service. Official website: https://www.alector.com/ (opens in a new window)[12][17]
Maze Therapeutics: Board service. Official website: https://mazetx.com/ (opens in a new window)[12][18]
Aarvik Therapeutics: Board service. Official website: https://aarviktx.com/ (opens in a new window)[12][19]
GondolaBio: Board service. Official website: https://gondolabio.com/ (opens in a new window)[12][20]
Xaira Therapeutics: Board service. Official website: https://www.xaira.com/ (opens in a new window)[12][21]
Trace Neuroscience: Board service. Official website: https://www.traceneuro.com/ (opens in a new window)[12][22]
Corporation of the Fine Arts Museums of San Francisco: Board service. Record of service: https://investors.alector.com/static-files/55730af4-76dc-41e7-aedd-eef267428f98 (opens in a new window)[12]
Sources22 sources
- Richard H. Scheller life story (opens in a new window)kavliprize.org↑
- Kavli Prize Laureate Richard H. Scheller (opens in a new window)kavliprize.org↑
- Richard H. Scheller Elected as Caltech Trustee (opens in a new window)caltech.edu↑
- Richard Scheller (opens in a new window)gv.com↑
- Richard Scheller (opens in a new window)roche.com↑
- Alector, Inc.: 2026 Proxy Statement (opens in a new window)sec.gov↑
- 23andMe Holding Co. — Form 8-K (opens in a new window)sec.gov↑
- Maze Therapeutics, Inc.: 2026 Proxy Statement (opens in a new window)sec.gov↑
- BridgeBio Pharma, Inc.: Current Report on Form 8-K (opens in a new window)sec.gov↑
- 23andMe ft. Anne Wojcicki - How a DNA startup took on the FDA and redefined health tech (opens in a new window)youtube.com↑
- 23andMe ft. Anne Wojcicki (opens in a new window)sequoiacap.com↑
- 2026 Proxy Statement (opens in a new window)investors.alector.com↑
- Richard Scheller, PhD (opens in a new window)aarviktx.com↑
- California Institute of Technology (opens in a new window)caltech.edu↑
- Xenon Pharmaceuticals (opens in a new window)xenon-pharma.com↑
- ORIC Pharmaceuticals (opens in a new window)oricpharma.com↑
- Alector (opens in a new window)alector.com↑
- Maze Therapeutics (opens in a new window)mazetx.com↑
- Aarvik Therapeutics (opens in a new window)aarviktx.com↑
- GondolaBio (opens in a new window)gondolabio.com↑
- Xaira Therapeutics (opens in a new window)xaira.com↑
- Trace Neuroscience (opens in a new window)traceneuro.com↑